Undetected cancer in clinical prostate biopsies
SND-ID: 2024-144. Version: 1. DOI: https://doi.org/10.57804/epa0-8v59
Download data
Associated documentation
Citation
Creator/Principal investigator(s)
Eduard Chelebian
- Uppsala University, Department of Information Technology
Carolina Wählby
- Uppsala University, Department of Information Technology
Anders Bergh
- Umeå University, Department of Medical Biosciences
Research principal
Description
This dataset comprises digitized benign prostate hematoxilyn and eosin (H&E) biopsies from men with raised prostate-specific antigen (PSA) values. The biopsies were systematically taken from different locations in the prostate and were not guided by magnetic resonance imaging (MRI). The dataset includes paired samples from patients with comparable age and PSA levels, all initially diagnosed as benign but with different outcomes upon subsequent follow-ups and re-biopsies. While some patients remained cancer-free during eight years of follow-up, others were diagnosed with prostate cancer within the subsequent 30 months of follow-up.
The final processed dataset includes 213 patients from northern Sweden, resulting in a total of 587 H&E prostate needle biopsies. Among these, 125 control patients with 333 biopsies exhibited no cancer development in eight years following the initial diagnosis. Conversely, 88 case patients with 254 biopsies were diagnosed with prostate cancer of various ISUP grades within the 30 months following the initial diagnosis. Each case patient is accompanied by one to three
The final processed dataset includes 213 patients from northern Sweden, resulting in a total of 587 H&E prostate needle biopsies. Among these, 125 control patients with 333 biopsies exhibited no cancer development in eight years following the initial diagnosis. Conversely, 88 case patients with 254 biopsies were diagnosed with prostate cancer of various ISUP grades within the 30 months following the initial diagnosis. Each case patient is accompanied by one to three control patients, paired for similar age, PSA value and year of diagnosis.
Patients were anonymized by assigning random case IDs and MRXS image files were anonymized by using the module in https://github.com/bgilbert/anonymize-slide. Show less..
Data contains personal data
No
Language
Unit of analysis
Population
Anonymised men from northern Sweden with raised serum prostate-specific antigen (PSA), an initial benign diagnosis in prostate needle biopsies and with subsequent separation in diagnostic trajectories.
Study design
Cohort study: Retrospective
Time period(s) investigated
1997 – 2016
Number of individuals/objects
213
Data format / data structure
Other research principals
Contributor(s)
Christophe Avenel
- Uppsala University, Department of Information Technology
Pernilla Andersson - Umeå University, Department of Medical Biosciences
Helena Järemo
- Umeå University, Department of Medical Biosciences
Ethics Review
Umeå - Ref. Regionala Etikprövningsnämnden, 2010/366-31M
Research area
Science and technology (CESSDA Topic Classification)
Information technology (CESSDA Topic Classification)
Computer vision and robotics (autonomous systems) (Standard för svensk indelning av forskningsämnen 2011)
Medical image processing (Standard för svensk indelning av forskningsämnen 2011)
Medical and health sciences (Standard för svensk indelning av forskningsämnen 2011)
Cancer and oncology (Standard för svensk indelning av forskningsämnen 2011)
Urology and nephrology (Standard för svensk indelning av forskningsämnen 2011)
Keywords
Pathology, Histological techniques, Image processing, computer-assisted, Neoplasms by histologic type, Staining and labeling, Prostate-specific antigen, Computational biology, Malignant neoplasm of prostate, Benign neoplasm: prostate, Prostate cancer screening, Prostate cancer, Whole-slide image, Computational pathology
